Approved for Treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise ability. Tadalafil inhibits phosphodiesterase type 5 (PDE5) in pulmonary vascular smooth muscle, increasing cyclic GMP levels. This produces vasodilation of the pulmonary vasculature and reduces pulmonary… Side effects, costs, interactions, manufacturer, and generic alternatives sourced from FDA labels,…
Loading full data from Know Your Drugs Institute…